Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
81 hedge funds and large institutions have $287M invested in Avadel Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 8 closing their positions.
928% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $1.6M
43% more capital invested
Capital invested by funds: $200M → $287M (+$86.3M)
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1% more funds holding
Funds holding: 80 → 81 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.22% less ownership
Funds ownership: 55.91% → 54.69% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$11.8M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$3.15M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
+$2.94M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.59M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$833K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$16.5M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.42M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$1.39M |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$1.36M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$1.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BWP
76
Baldwin Wealth Partners
Marion,
Massachusetts
| $4K | – | – | – |
|
|
RMC
77
Resources Management Corp
West Hartford,
Connecticut
| $4K | +$3.15K | +400 | New |
|
|
SPIA
78
Steward Partners Investment Advisory
New York
| $3K | – | – | – |
|
79
Barclays
London,
United Kingdom
| $1K | -$4.36K | -554 | -78% |
|
|
ARMC
80
American Research & Management Company
Marion,
Massachusetts
| $1K | – | – | – |
|
81
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
ACP
82
Acuta Capital Partners
Redwood City,
California
| – | -$4.42M | -561,011 | Closed |
|
|
PVI
83
Pura Vida Investments
New York
| – | -$1.39M | -176,206 | Closed |
|
84
Squarepoint
New York
| – | -$190K | -28,162 | Closed |
|
85
Jane Street
New York
| – | -$137K | -17,397 | Closed |
|
|
EGM
86
Engineers Gate Manager
New York
| – | -$93K | -13,800 | Closed |
|
|
JF
87
Jump Financial
Chicago,
Illinois
| – | -$92K | -13,712 | Closed |
|
|
HI
88
Harbour Investments
Madison,
Wisconsin
| – | -$2K | -300 | Closed |
|
|
PA
89
Parallel Advisors
San Francisco,
California
| – | -$1K | -128 | Closed |
|
AVDL Hedge Fund Activity: Q3 2021 in Review
81 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2021, worth a combined $287M — up 43% from $200M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AVDL positions and 8 closed out — a net gain of 1 holder — while 28 added to existing stakes and 21 trimmed.
The largest buyer was Woodline Partners, adding an estimated $11.8M. The largest seller was Avoro Capital Advisors, cutting an estimated $16.5M.
- 81 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2021, up from 80 in Q2 2021.
- Funds reported $287M of Avadel Pharmaceuticals stock for Q3 2021, up 43% quarter-over-quarter.
- 9 funds opened new Avadel Pharmaceuticals positions in Q3 2021 and 8 closed out, a net change of +1 holder.
- The largest Avadel Pharmaceuticals buyer in Q3 2021 was Woodline Partners, an estimated $11.8M added.
- The largest Avadel Pharmaceuticals seller in Q3 2021 was Avoro Capital Advisors, an estimated $16.5M sold.
Based on aggregated 13F filings for Q3 2021.